Key points are not available for this paper at this time.
Abstract Introduction Hepcidin is a peptide associated with controlling the distribution of iron in tissues. Growing interest is linked with its impact on neurodegenerative diseases, as disruption of the iron regulation may be considered an initiatory element of pathological protein accumulation. The possible impact of hepcidin was not previously sufficiently explored in progressive supranuclear palsy (PSP). Methods Twelve patients with PSP–Richardson's syndrome (PSP–RS), 12 with PSP‐Parkinsonism Predominant (PSP‐P), and 12 controls were examined using Unified Parkinson's Disease Rating Scale—III part (UPDRS‐III) in OFF stage and analyzed in the context of hepcidin levels in the serum. Results The work revealed increased levels of hepcidin in PSP–RS when compared to PSP‐P and controls. Moreover, hepcidin was found to be negatively correlated with UPDRS‐III results in PSP–RS, whereas positively in PSP‐P. Conclusion The work may suggest a possible impact of hepcidin in PSP, possibly differing depending on its subtype.
Alster et al. (Sat,) studied this question.